Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "TILT[LastUpdatePostDate]SEARCH[Study]AREA[SponsorSearch]Infinity Pharmaceuticals, Inc."
Count: 28
Selected: 0
NCT IDTitle
NCT03980041Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
NCT03961698Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3)
NCT02637531A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549
NCT01130142A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer
NCT01193491Dose Escalation of IPI-493 in Hematologic Malignancies
NCT00724425A Phase 1 Dose Escalation Study of IPI-493
NCT00969917Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma
NCT01427946Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer
NCT01362400A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
NCT01310816A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma
NCT00817362Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer
NCT00688766Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib
NCT00564928A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer
NCT00627419A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma
NCT00431015Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)
NCT01371617A Phase 2 Study With IPI-926 in Patients With Myelofibrosis
NCT01609179IPI-926 Extension Protocol for Continuation of Treatment With IPI-926
NCT00761696A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies
NCT00606814Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors
NCT00276302Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)
NCT00113204Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma
NCT03719326A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies
NCT01383538FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma
NCT02598570Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma
NCT02640833A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor
NCT01871675Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies
NCT02028039IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)
NCT01228435IPI-504 in NSCLC Patients With ALK Translocations